CMO/CDMO 생명공학 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2033년)

CMO/CDMO Biotechnology Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

US $ 4,995 ￦ 7,411,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,823,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,604,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 세계 CMO/CDMO(의약품 제조 수탁기관/연구개발수탁기관) 생명공학 시장의 상세한 분석을 발표했습니다. 이 보고서는 성장 촉진요인, 동향, 시장 성장 촉진요인 및 과제를 포함한 주요 시장 역학을 종합적으로 평가하여 시장 전망에 대한 철저한 이해를 제공합니다.

주요 인사이트

• CMO/CDMO 생명공학 시장 규모(2024E) : 231억 달러
• 예측 시장 가치(2033F) : 336억 달러
• 세계 시장 성장률(CAGR 2024년부터 2033년까지) : 5.5%

CMO/CDMO 생명공학 시장 - 조사 범위:

CMO/CDMO 생명공학 시장은 바이오 의약품 업계에서 중요한 부분이며, 생명공학 제품의 제조 및 시장 개척 서비스의 아웃소싱에 중점을 둡니다. 이 시장에는 전문 조직이 바이오 의약품 기업에 제공하는 의약품 개발, 제조 및 상업화와 같은 광범위한 서비스가 포함됩니다. 이 분야의 특징은 의약품 개발 기간의 단축, 운영 비용의 절감, 제조 능력의 강화에 맡는 역할에 있습니다. 시장 확대는 생명 공학 치료에 대한 수요 증가, 의약품 개발의 복잡화, 유연하고 확장 가능한 제조 솔루션의 필요성 등이 배경에 있습니다.

시장 성장 촉진요인:

CMO/CDMO 생명공학 시장은 생물학적 제제와 개인화된 의료에 대한 수요 증가 등 몇 가지 중요한 요인에 의해 활성화되고 있습니다. 바이오 의약품 기업은 CMO/CDMO 공급자의 전문 지식, 첨단 기술 및 비용 효율성을 활용하기 위해 제조 아웃소싱을 점점 더 진행하고 있습니다. 생물 제제와 복잡한 의약품으로의 전환은 신속한 시장 진입과 유연성의 필요성과 함께 CMO/CDMO 부문의 성장을 뒷받침하고 있습니다. 게다가 만성 질환 증가와 신약 치료에 대한 관심 증가도 바이오 의약품 제조 서비스의 아웃소싱 수요 증가에 기여하고 있습니다.

시장 성장 억제요인:

성장의 가능성은 CMO/CDMO 생명공학 시장은 규제의 복잡성, 지적 재산권에 대한 우려, 경쟁 격화 등의 과제에 직면하고 있습니다. 생명 공학 제품의 규제 상황을 극복하기 위해서는 엄격한 기준을 준수해야하며 CMO/CDMO 공급자에게는 어려움이 동반됩니다. 또한, 제제나 제법에 관한 지적재산의 문제도 리스크가 될 수 있습니다. 게다가 시장 경쟁은 치열하고 많은 기업들이 계약을 다투고 있기 때문에 가격 및 이익률에 영향을 미칠 수 있습니다.

시장 기회:

CMO/CDMO 생명공학 시장은 기술 진보, 바이오 의약품 투자 증가, 치료 영역 확대로 큰 성장 기회를 제공합니다. 단일 사용 시스템 및 연속 제조와 같은 바이오 제조 기술의 혁신은 시장 기업에게 효율성 향상과 비용 절감 기회를 제공합니다. 생물 제제와 유전자 치료의 대두는 CMO/CDMO 제공업체가 틈새 부문에 대응하고 전문 서비스를 개발하는 새로운 길을 열었습니다. 또한 CMO/CDMO 기업과 바이오 제약 기업 간의 전략적 제휴는 시장 성장을 가속하고 혁신을 촉진할 수 있습니다.

이 보고서에서 다루는 주요 질문

• 세계 CMO/CDMO 생명공학 시장의 성장을 가속하는 주요 요인은?
• 큰 수요가 있는 CMO/CDMO 서비스와 치료 분야는?
• 기술의 진보는 CMO/CDMO 시장 경쟁 구도를 어떻게 바꾸고 있는가?
• CMO/CDMO 생명 공학 시장의 주요 기업은 누구이며 경쟁력을 유지하기 위해 어떤 전략을 취하고 있는가?
• 세계의 CMO/CDMO 생명공학 시장의 새로운 동향과 장래성은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위/분류
• 시장의 정의/범위/제한
• 포함과 제외

제3장 주요 시장 동향

• 시장에 영향을 주는 주요 동향
• 혁신/개발 동향

제4장 중요한 성공 요인

• 서비스 채용 분석
• 주요 규제
• 주요 기업에 의한 주요 프로모션 전략
• PESTEL 분석
• 서비스 가격 분석

제5장 시장 배경

• 거시경제 요인
• 예측 요인- 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• COVID-19와 영향 분석
  • 서비스별
  • 제품별
  • 표현 시스템별
  • 기업 규모별
  • 사업 규모별
  • 국가별
• 2024년 시장 시나리오

제7장 세계 CMO/CDMO 생명공학 시장 수요(금액 또는 규모, 10억 달러) 분석

• 시장 매출(10억 달러) 분석, 2019-2023년
• 시장 매출(10억 달러) 예측, 2024-2033년
  • 전년대비 성장 동향 분석
  • 절대 수익 기회

제8장 세계의 CMO/CDMO 생명공학 시장 분석 : 서비스별

• 소개/주요 조사 결과
• 시장 규모(10억 달러) 분석, 2019-2023년
• 시장 규모(10억 달러) 분석과 예측, 2024-2033년
  • 독립형 서비스
    • 세포주 개발
    • 개발과 바이오 제조
    • 분석 서비스
    • 충전 마무리
    • 패키지
    • 임상 공급 서비스
  • 통합형
• 서비스별 시장의 매력 분석

제9장 세계의 CMO/CDMO 생명공학 시장 분석 : 제품별

• 소개/주요 조사 결과
• 시장 규모(10억 달러) 분석, 2019-2023년
• 시장 규모(10억 달러) 분석과 예측, 2024-2033년
  • 단클론항체
  • 항체 단편
  • 재조합 치료용 단백질
  • 바이러스 벡터
  • 세포 및 유전자 치료
  • 백신
• 제품별 시장의 매력 분석

제10장 세계의 CMO/CDMO 생명공학 시장 분석 : 발현 시스템별

• 소개/주요 조사 결과
• 시장 규모(10억 달러) 분석, 2019-2023년
• 시장 규모(10억 달러) 분석과 예측, 2024-2033년
  • 포유류
  • 미생물
    • 박테리아
    • 효모
• 발현 시스템별 시장의 매력 분석

제11장 세계의 CMO/CDMO 생명공학 시장 분석 : 기업 규모별

• 소개/주요 조사 결과
• 시장 규모(10억 달러) 분석, 2019-2023년
• 시장 규모(10억 달러) 분석과 예측, 2024-2033년
  • 소규모
  • 중규모
  • 대규모
  • 초대규모
• 기업 규모별 시장의 매력 분석

제12장 세계의 CMO/CDMO 생명공학 시장 분석 : 운영 규모별

• 소개/주요 조사 결과
• 시장 규모(10억 달러) 분석, 2019-2023년
• 시장 규모(10억 달러) 분석과 예측, 2024-2033년
  • 전임상
  • 임상
  • 상업
• 운용 규모별 시장의 매력 분석

제13장 세계의 CMO/CDMO 생명공학 시장 분석 : 지역별

• 소개
• 시장 규모(10억 달러) 분석, 2019-2023년
• 시장 규모(10억 달러) 분석과 예측, 2024-2033년
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아
  • 오세아니아
  • 중동 및 아프리카
• 지역별 시장의 매력 분석

제14장 북미 CMO/CDMO 생명공학 시장 분석

제15장 라틴아메리카의 CMO/CDMO 생명공학 시장 분석

제16장 유럽의 CMO/CDMO 생명공학 시장 분석

제17장 동아시아의 CMO/CDMO 생명공학 시장 분석

제18장 남아시아의 CMO/CDMO 생명공학 시장 분석

제19장 오세아니아의 CMO/CDMO 생명공학 시장

제20장 중동 및 아프리카 CMO/CDMO 생명공학 시장 분석

제21장 시장 구조 분석

• 기업 Tier별 시장 분석
• 주요 기업의 시장 점유율 분석
• 시장현재분석

제22장 경쟁 분석

• 경쟁 대시보드
• 경쟁의 상세
  • Patheon NV
  • Catalent
  • Samsung Biologics Co., Ltd
  • Lonza.
  • Boehringer Ingelheim
  • Samsung BioLogics
  • AGC Biologics, Inc.
  • WuXi Biologics
  • AbbVie Inc
  • Avid Bioservices, Inc.
  • Fujifilm Diosynth Biotechnologies
  • Xpress Biologic
  • Rentschler Biopharma SE
  • KBI Biopharma(JSR Corporation)
  • Cytovance Biologics

제23장 사용된 전제조건과 약어

제24장 조사 방법

JHS

영문 목차

영문목차

Persistence Market Research has recently published an in-depth analysis of the global CMO/CDMO (Contract Manufacturing Organization/Contract Development and Manufacturing Organization) biotechnology market. The report provides a comprehensive evaluation of key market dynamics, including growth drivers, trends, opportunities, and challenges, delivering a thorough understanding of the market landscape.

Key Insights:

• CMO/CDMO Biotechnology Market Size (2024E): USD 23.1 Bn
• Projected Market Value (2033F): USD 33.6 Bn
• Global Market Growth Rate (CAGR 2024 to 2033): 5.5%

CMO/CDMO Biotechnology Market - Report Scope:

The CMO/CDMO biotechnology market represents a crucial segment in the biopharmaceutical industry, focusing on the outsourcing of manufacturing and development services for biotech products. This market includes a wide range of services, such as drug development, manufacturing, and commercialization, provided by specialized organizations to biopharma companies. The sector is characterized by its role in accelerating drug development timelines, reducing operational costs, and enhancing manufacturing capabilities. The market's expansion is driven by the growing demand for biotech therapies, increasing complexity in drug development, and the need for flexible and scalable manufacturing solutions.

Market Growth Drivers:

The CMO/CDMO biotechnology market is fueled by several key factors, including the rising demand for biologics and personalized medicine. Biopharma companies are increasingly outsourcing manufacturing to CMO/CDMO providers to leverage their specialized expertise, advanced technologies, and cost efficiencies. The shift towards biologics and complex drugs, coupled with the need for rapid market entry and flexibility, drives the growth of the CMO/CDMO sector. Additionally, the increasing prevalence of chronic diseases and the growing focus on novel drug therapies contribute to the rising demand for outsourced biotech manufacturing services.

Market Restraints:

Despite its growth potential, the CMO/CDMO biotechnology market faces challenges such as regulatory complexities, intellectual property concerns, and high competition. Navigating the regulatory landscape for biotech products requires adherence to stringent standards, which can be challenging for CMO/CDMO providers. Intellectual property issues related to drug formulations and processes may also pose risks. Furthermore, the market is highly competitive, with numerous players vying for contracts, which can impact pricing and profit margins.

Market Opportunities:

The CMO/CDMO biotechnology market offers substantial growth opportunities driven by technological advancements, increasing investments in biopharma, and expanding therapeutic areas. Innovations in biomanufacturing technologies, such as single-use systems and continuous manufacturing, present opportunities for market players to enhance efficiency and reduce costs. The rise of biologics and gene therapies opens new avenues for CMO/CDMO providers to cater to niche segments and develop specialized services. Strategic collaborations between CMO/CDMO firms and biopharma companies can also drive market growth and foster innovation.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the CMO/CDMO biotechnology market globally?
• Which CMO/CDMO services and therapeutic areas are experiencing significant demand?
• How are technological advancements reshaping the competitive landscape of the CMO/CDMO market?
• Who are the key players in the CMO/CDMO biotechnology market, and what strategies are they employing to maintain a competitive edge?
• What are the emerging trends and future prospects in the global CMO/CDMO biotechnology market?

Competitive Intelligence and Business Strategy:

Leading players in the global CMO/CDMO biotechnology market, such as Lonza Group, Catalent, and Samsung Biologics, emphasize innovation, service differentiation, and strategic partnerships to enhance their market position. These companies invest in advanced manufacturing technologies, expand their service portfolios, and forge alliances with biopharma firms to strengthen their competitive edge. Focus on operational excellence, regulatory compliance, and customer-centric solutions is critical for maintaining market relevance and driving growth in the highly competitive CMO/CDMO sector.

Key Companies Profiled:

• Patheon N.V.
• Catalent
• Samsung Biologics Co., Ltd
• Lonza.
• Boehringer Ingelheim
• Samsung BioLogics
• AGC Biologics, Inc.
• WuXi Biologics
• AbbVie Inc
• Avid Bioservices, Inc.
• Fujifilm Diosynth Biotechnologies
• Xpress Biologic
• Rentschler Biopharma SE
• KBI Biopharma (JSR Corporation)
• Cytovance Biologics

Key Segments Covered in CMO/CDMO Biotechnology Industry Research

By Service:

• Stand-Alone Services
• Integrated

By Product:

• Monoclonal Antibodies
• Antibody Fragments
• Recombinant Therapeutic Proteins
• Viral Vector
• Cell and Gene Therapy
• Vaccine

By Expression System:

• Mammalian
• Microbial
• Bacteria
• Yeast

By Company Size:

• Small
• Mid-Sized
• Large
• Very Large

By Scale of Operations:

• Pre-clinical
• Clinical
• Commercial

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Innovation / Development Trends

4. Key Success Factors

• 4.1. Service Adoption Analysis
• 4.2. Key Regulations
• 4.3. Key promotional Strategies, By Key Players
• 4.4. PESTEL Analysis
• 4.5. Service Pricing Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Outlook
  • 5.1.3. Global CMO/CDMO Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Increase in R&D Spending
  • 5.2.2. Growing Lifestyle Disease Prevalence
  • 5.2.3. Cost of Services
  • 5.2.4. Service Adoption Rate
  • 5.2.5. Advancements in Technology
  • 5.2.6. Changes in Regulatory Policies
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Services
  • 6.1.2. By Product
  • 6.1.3. By Expression Systems
  • 6.1.4. By Company Size
  • 6.1.5. By Scale of Operations
  • 6.1.6. By Country
• 6.2. 2024 Market Scenario

7. Global CMO/CDMO Biotechnology Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Services

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Bn) Analysis By Services, 2019-2023
• 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Services, 2024-2033
  • 8.3.1. Stand-Alone Services
    • 8.3.1.1. Cell Line Development
    • 8.3.1.2. Development and Bio Manufacturing
    • 8.3.1.3. Analytical Services
    • 8.3.1.4. Fill finish
    • 8.3.1.5. Packaging
    • 8.3.1.6. Clinical Supply Services
  • 8.3.2. Integrated
• 8.4. Market Attractiveness Analysis By Services

9. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Product

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019-2023
• 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product, 2024-2033
  • 9.3.1. Monoclonal Antibodies
  • 9.3.2. Antibody Fragments
  • 9.3.3. Recombinant Therapeutic Proteins
  • 9.3.4. Viral Vector
  • 9.3.5. Cell and Gene Therapy
  • 9.3.6. Vaccine
• 9.4. Market Attractiveness Analysis By Product

10. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Expression Systems

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Bn) Analysis, By Expression Systems, 2019-2023
• 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Expression Systems, 2024-2033
  • 10.3.1. Mammalian
  • 10.3.2. Microbial
    • 10.3.2.1. Bacteria
    • 10.3.2.2. Yeast
• 10.4. Market Attractiveness Analysis By Expression Systems

11. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Company Size

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Bn) Analysis, By Company Size, 2019-2023
• 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Company Size, 2024-2033
  • 11.3.1. Small
  • 11.3.2. Mid-sized
  • 11.3.3. Large
  • 11.3.4. Very large
• 11.4. Market Attractiveness Analysis By Company Size

12. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Scale of Operation

• 12.1. Introduction / Key Findings
• 12.2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019-2023
• 12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Scale of Operation, 2024-2033
  • 12.3.1. Preclinical
  • 12.3.2. Clinical
  • 12.3.3. Commercial
• 12.4. Market Attractiveness Analysis By Scale of Operation

13. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
• 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
  • 13.3.1. North America
  • 13.3.2. Latin America
  • 13.3.3. Europe
  • 13.3.4. East Asia
  • 13.3.5. South Asia
  • 13.3.6. Oceania
  • 13.3.7. Middle East and Africa (MEA)
• 13.4. Market Attractiveness Analysis By Region

14. North America CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. U.S.
    • 14.3.1.2. Canada
  • 14.3.2. By Services
  • 14.3.3. By Product
  • 14.3.4. By Expression Systems
  • 14.3.5. By Company Size
  • 14.3.6. By Scale of Operation
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Services
  • 14.4.3. By Product
  • 14.4.4. By Expression Systems
  • 14.4.5. By Company Size
  • 14.4.6. By Scale of Operation
• 14.5. Market Trends
• 14.6. Drivers and Restraints - Impact Analysis
• 14.7. Key Players - Intensity Mapping
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. U.S. CMO/CDMO Biotechnology Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Services
      • 14.8.1.2.2. By Product
      • 14.8.1.2.3. By Expression Systems
      • 14.8.1.2.4. By Company Size
      • 14.8.1.2.5. By Scale of Operation
  • 14.8.2. Canada CMO/CDMO Biotechnology Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Services
      • 14.8.2.2.2. By Product
      • 14.8.2.2.3. By Expression Systems
      • 14.8.2.2.4. By Company Size
      • 14.8.2.2.5. By Scale of Operation

15. Latin America CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. Mexico
    • 15.3.1.2. Brazil
    • 15.3.1.3. Argentina
    • 15.3.1.4. Rest of Latin America
  • 15.3.2. By Services
  • 15.3.3. By Product
  • 15.3.4. By Expression Systems
  • 15.3.5. By Company Size
  • 15.3.6. By Scale of Operation
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Services
  • 15.4.3. By Product
  • 15.4.4. By Expression Systems
  • 15.4.5. By Company Size
  • 15.4.6. By Scale of Operation
• 15.5. Market Trends
• 15.6. Drivers and Restraints - Impact Analysis
• 15.7. Key Players - Intensity Mapping
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. Mexico CMO/CDMO Biotechnology Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Services
      • 15.8.1.2.2. By Product
      • 15.8.1.2.3. By Expression Systems
      • 15.8.1.2.4. By Company Size
      • 15.8.1.2.5. By Scale of Operation
  • 15.8.2. Brazil CMO/CDMO Biotechnology Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Services
      • 15.8.2.2.2. By Product
      • 15.8.2.2.3. By Expression Systems
      • 15.8.2.2.4. By Company Size
      • 15.8.2.2.5. By Scale of Operation
  • 15.8.3. Argentina CMO/CDMO Biotechnology Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Services
      • 15.8.3.2.2. By Product
      • 15.8.3.2.3. By Expression Systems
      • 15.8.3.2.4. By Company Size
      • 15.8.3.2.5. By Scale of Operation

16. Europe CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. Germany
    • 16.3.1.2. Italy
    • 16.3.1.3. France
    • 16.3.1.4. U.K.
    • 16.3.1.5. Spain
    • 16.3.1.6. BENELUX
    • 16.3.1.7. Russia
    • 16.3.1.8. Rest of Europe
  • 16.3.2. By Services
  • 16.3.3. By Product
  • 16.3.4. By Expression Systems
  • 16.3.5. By Company Size
  • 16.3.6. By Scale of Operation
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Services
  • 16.4.3. By Product
  • 16.4.4. By Expression Systems
  • 16.4.5. By Company Size
  • 16.4.6. By Scale of Operation
• 16.5. Market Trends
• 16.6. Drivers and Restraints - Impact Analysis
• 16.7. Key Players - Intensity Mapping
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. Germany CMO/CDMO Biotechnology Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Services
      • 16.8.1.2.2. By Product
      • 16.8.1.2.3. By Expression Systems
      • 16.8.1.2.4. By Company Size
      • 16.8.1.2.5. By Scale of Operation
  • 16.8.2. Italy CMO/CDMO Biotechnology Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Services
      • 16.8.2.2.2. By Product
      • 16.8.2.2.3. By Expression Systems
      • 16.8.2.2.4. By Company Size
      • 16.8.2.2.5. By Scale of Operation
  • 16.8.3. France CMO/CDMO Biotechnology Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Services
      • 16.8.3.2.2. By Product
      • 16.8.3.2.3. By Expression Systems
      • 16.8.3.2.4. By Company Size
      • 16.8.3.2.5. By Scale of Operation
  • 16.8.4. U.K. CMO/CDMO Biotechnology Market Analysis
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.4.2.1. By Services
      • 16.8.4.2.2. By Product
      • 16.8.4.2.3. By Expression Systems
      • 16.8.4.2.4. By Company Size
      • 16.8.4.2.5. By Scale of Operation
  • 16.8.5. Spain CMO/CDMO Biotechnology Market Analysis
    • 16.8.5.1. Introduction
    • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.5.2.1. By Services
      • 16.8.5.2.2. By Product
      • 16.8.5.2.3. By Expression Systems
      • 16.8.5.2.4. By Company Size
      • 16.8.5.2.5. By Scale of Operation
  • 16.8.6. BENELUX CMO/CDMO Biotechnology Market Analysis
    • 16.8.6.1. Introduction
    • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.6.2.1. By Services
      • 16.8.6.2.2. By Product
      • 16.8.6.2.3. By Expression Systems
      • 16.8.6.2.4. By Company Size
      • 16.8.6.2.5. By Scale of Operation
  • 16.8.7. Russia CMO/CDMO Biotechnology Market Analysis
    • 16.8.7.1. Introduction
    • 16.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.7.2.1. By Services
      • 16.8.7.2.2. By Product
      • 16.8.7.2.3. By Expression Systems
      • 16.8.7.2.4. By Company Size
      • 16.8.7.2.5. By Scale of Operation

17. East Asia CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. China
    • 17.3.1.2. Japan
    • 17.3.1.3. South Korea
  • 17.3.2. By Services
  • 17.3.3. By Product
  • 17.3.4. By Expression Systems
  • 17.3.5. By Company Size
  • 17.3.6. By Scale of Operation
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Services
  • 17.4.3. By Product
  • 17.4.4. By Expression Systems
  • 17.4.5. By Company Size
  • 17.4.6. By Scale of Operation
• 17.5. Market Trends
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Key Players - Intensity Mapping
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. China CMO/CDMO Biotechnology Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Services
      • 17.8.1.2.2. By Product
      • 17.8.1.2.3. By Expression Systems
      • 17.8.1.2.4. By Company Size
      • 17.8.1.2.5. By Scale of Operation
  • 17.8.2. Japan CMO/CDMO Biotechnology Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Services
      • 17.8.2.2.2. By Product
      • 17.8.2.2.3. By Expression Systems
      • 17.8.2.2.4. By Company Size
      • 17.8.2.2.5. By Scale of Operation
  • 17.8.3. South Korea CMO/CDMO Biotechnology Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Services
      • 17.8.3.2.2. By Product
      • 17.8.3.2.3. By Expression Systems
      • 17.8.3.2.4. By Company Size
      • 17.8.3.2.5. By Scale of Operation

18. South Asia CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 18.3.1. By Country
    • 18.3.1.1. India
    • 18.3.1.2. Indonesia
    • 18.3.1.3. Malaysia
    • 18.3.1.4. Thailand
    • 18.3.1.5. Rest of South Asia
  • 18.3.2. By Services
  • 18.3.3. By Product
  • 18.3.4. By Expression Systems
  • 18.3.5. By Company Size
  • 18.3.6. By Scale of Operation
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Services
  • 18.4.3. By Product
  • 18.4.4. By Expression Systems
  • 18.4.5. By Company Size
  • 18.4.6. By Scale of Operation
• 18.5. Market Trends
• 18.6. Drivers and Restraints - Impact Analysis
• 18.7. Key Players - Intensity Mapping
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. India CMO/CDMO Biotechnology Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Services
      • 18.8.1.2.2. By Product
      • 18.8.1.2.3. By Expression Systems
      • 18.8.1.2.4. By Company Size
      • 18.8.1.2.5. By Scale of Operation
  • 18.8.2. Indonesia CMO/CDMO Biotechnology Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Services
      • 18.8.2.2.2. By Product
      • 18.8.2.2.3. By Expression Systems
      • 18.8.2.2.4. By Company Size
      • 18.8.2.2.5. By Scale of Operation
  • 18.8.3. Malaysia CMO/CDMO Biotechnology Market Analysis
    • 18.8.3.1. Introduction
    • 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.3.2.1. By Services
      • 18.8.3.2.2. By Product
      • 18.8.3.2.3. By Expression Systems
      • 18.8.3.2.4. By Company Size
      • 18.8.3.2.5. By Scale of Operation
  • 18.8.4. Thailand CMO/CDMO Biotechnology Market Analysis
    • 18.8.4.1. Introduction
    • 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.4.2.1. By Services
      • 18.8.4.2.2. By Product
      • 18.8.4.2.3. By Expression Systems
      • 18.8.4.2.4. By Company Size
      • 18.8.4.2.5. By Scale of Operation

19. Oceania CMO/CDMO Biotechnology Market 2019-2023 and Forecast 2024-2033

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 19.3.1. By Country
    • 19.3.1.1. Australia
    • 19.3.1.2. New Zealand
  • 19.3.2. By Services
  • 19.3.3. By Product
  • 19.3.4. By Expression Systems
  • 19.3.5. By Company Size
  • 19.3.6. By Scale of Operation
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By Services
  • 19.4.3. By Product
  • 19.4.4. By Expression Systems
  • 19.4.5. By Company Size
  • 19.4.6. By Scale of Operation
• 19.5. Market Trends
• 19.6. Drivers and Restraints - Impact Analysis
• 19.7. Key Players - Intensity Mapping
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. Australia CMO/CDMO Biotechnology Market Analysis
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Services
      • 19.8.1.2.2. By Product
      • 19.8.1.2.3. By Expression Systems
      • 19.8.1.2.4. By Company Size
      • 19.8.1.2.5. By Scale of Operation
  • 19.8.2. New Zealand CMO/CDMO Biotechnology Market Analysis
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Services
      • 19.8.2.2.2. By Product
      • 19.8.2.2.3. By Expression Systems
      • 19.8.2.2.4. By Company Size
      • 19.8.2.2.5. By Scale of Operation

20. Middle East and Africa (MEA) CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 20.1. Introduction
• 20.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 20.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 20.3.1. By Country
    • 20.3.1.1. GCC Countries
    • 20.3.1.2. Turkey
    • 20.3.1.3. North Africa
    • 20.3.1.4. South Africa
    • 20.3.1.5. Rest of Middle East and Africa
  • 20.3.2. By Services
  • 20.3.3. By Product
  • 20.3.4. By Expression Systems
  • 20.3.5. By Company Size
  • 20.3.6. By Scale of Operation
• 20.4. Market Attractiveness Analysis
  • 20.4.1. By Country
  • 20.4.2. By Services
  • 20.4.3. By Product
  • 20.4.4. By Expression Systems
  • 20.4.5. By Company Size
  • 20.4.6. By Scale of Operation
• 20.5. Market Trends
• 20.6. Drivers and Restraints - Impact Analysis
• 20.7. Key Players - Intensity Mapping
• 20.8. Country Level Analysis & Forecast
  • 20.8.1. GCC Countries CMO/CDMO Biotechnology Market Analysis
    • 20.8.1.1. Introduction
    • 20.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.1.2.1. By Services
      • 20.8.1.2.2. By Product
      • 20.8.1.2.3. By Expression Systems
      • 20.8.1.2.4. By Company Size
      • 20.8.1.2.5. By Scale of Operation
  • 20.8.2. Turkey CMO/CDMO Biotechnology Market Analysis
    • 20.8.2.1. Introduction
    • 20.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.2.2.1. By Services
      • 20.8.2.2.2. By Product
      • 20.8.2.2.3. By Expression Systems
      • 20.8.2.2.4. By Company Size
      • 20.8.2.2.5. By Scale of Operation
  • 20.8.3. South Africa CMO/CDMO Biotechnology Market Analysis
    • 20.8.3.1. Introduction
    • 20.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.3.2.1. By Services
      • 20.8.3.2.2. By Product
      • 20.8.3.2.3. By Expression Systems
      • 20.8.3.2.4. By Company Size
      • 20.8.3.2.5. By Scale of Operation
  • 20.8.4. North Africa CMO/CDMO Biotechnology Market Analysis
    • 20.8.4.1. Introduction
    • 20.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.4.2.1. By Services
      • 20.8.4.2.2. By Product
      • 20.8.4.2.3. By Expression Systems
      • 20.8.4.2.4. By Company Size
      • 20.8.4.2.5. By Scale of Operation

21. Market Structure Analysis

• 21.1. Market Analysis by Tier of Companies
• 21.2. Market Share Analysis of Top Players
• 21.3. Market Presence Analysis

22. Competition Analysis

• 22.1. Competition Dashboard
• 22.2. Competition Deep Dive
  • 22.2.1. Patheon N.V.
    • 22.2.1.1. Overview
    • 22.2.1.2. Service/Product Portfolio
    • 22.2.1.3. Sales Footprint
    • 22.2.1.4. Key Financials
    • 22.2.1.5. SWOT Analysis
    • 22.2.1.6. Strategy Overview
      • 22.2.1.6.1. Marketing Strategy
      • 22.2.1.6.2. Service Strategy
      • 22.2.1.6.3. Channel Strategy
  • 22.2.2. Catalent
    • 22.2.2.1. Overview
    • 22.2.2.2. Service/Product Portfolio
    • 22.2.2.3. Sales Footprint
    • 22.2.2.4. Key Financials
    • 22.2.2.5. SWOT Analysis
    • 22.2.2.6. Strategy Overview
      • 22.2.2.6.1. Marketing Strategy
      • 22.2.2.6.2. Service Strategy
      • 22.2.2.6.3. Channel Strategy
  • 22.2.3. Samsung Biologics Co., Ltd
    • 22.2.3.1. Overview
    • 22.2.3.2. Service/Product Portfolio
    • 22.2.3.3. Sales Footprint
    • 22.2.3.4. Key Financials
    • 22.2.3.5. SWOT Analysis
    • 22.2.3.6. Strategy Overview
      • 22.2.3.6.1. Marketing Strategy
      • 22.2.3.6.2. Service Strategy
      • 22.2.3.6.3. Channel Strategy
  • 22.2.4. Lonza.
    • 22.2.4.1. Overview
    • 22.2.4.2. Service/Product Portfolio
    • 22.2.4.3. Sales Footprint
    • 22.2.4.4. Key Financials
    • 22.2.4.5. SWOT Analysis
    • 22.2.4.6. Strategy Overview
      • 22.2.4.6.1. Marketing Strategy
      • 22.2.4.6.2. Service Strategy
      • 22.2.4.6.3. Channel Strategy
  • 22.2.5. Boehringer Ingelheim
    • 22.2.5.1. Overview
    • 22.2.5.2. Service/Product Portfolio
    • 22.2.5.3. Sales Footprint
    • 22.2.5.4. Key Financials
    • 22.2.5.5. SWOT Analysis
    • 22.2.5.6. Strategy Overview
      • 22.2.5.6.1. Marketing Strategy
      • 22.2.5.6.2. Service Strategy
      • 22.2.5.6.3. Channel Strategy
  • 22.2.6. Samsung BioLogics
    • 22.2.6.1. Overview
    • 22.2.6.2. Service/Product Portfolio
    • 22.2.6.3. Sales Footprint
    • 22.2.6.4. Key Financials
    • 22.2.6.5. SWOT Analysis
    • 22.2.6.6. Strategy Overview
      • 22.2.6.6.1. Marketing Strategy
      • 22.2.6.6.2. Service Strategy
      • 22.2.6.6.3. Channel Strategy
  • 22.2.7. AGC Biologics, Inc.
    • 22.2.7.1. Overview
    • 22.2.7.2. Service/Product Portfolio
    • 22.2.7.3. Sales Footprint
    • 22.2.7.4. Key Financials
    • 22.2.7.5. SWOT Analysis
    • 22.2.7.6. Strategy Overview
      • 22.2.7.6.1. Marketing Strategy
      • 22.2.7.6.2. Service Strategy
      • 22.2.7.6.3. Channel Strategy
  • 22.2.8. WuXi Biologics
    • 22.2.8.1. Overview
    • 22.2.8.2. Service/Product Portfolio
    • 22.2.8.3. Sales Footprint
    • 22.2.8.4. Key Financials
    • 22.2.8.5. SWOT Analysis
    • 22.2.8.6. Strategy Overview
      • 22.2.8.6.1. Marketing Strategy
      • 22.2.8.6.2. Service Strategy
      • 22.2.8.6.3. Channel Strategy
  • 22.2.9. AbbVie Inc
    • 22.2.9.1. Overview
    • 22.2.9.2. Service/Product Portfolio
    • 22.2.9.3. Sales Footprint
    • 22.2.9.4. Key Financials
    • 22.2.9.5. SWOT Analysis
    • 22.2.9.6. Strategy Overview
      • 22.2.9.6.1. Marketing Strategy
      • 22.2.9.6.2. Service Strategy
      • 22.2.9.6.3. Channel Strategy
  • 22.2.10. Avid Bioservices, Inc.
    • 22.2.10.1. Overview
    • 22.2.10.2. Service/Product Portfolio
    • 22.2.10.3. Sales Footprint
    • 22.2.10.4. Key Financials
    • 22.2.10.5. SWOT Analysis
    • 22.2.10.6. Strategy Overview
      • 22.2.10.6.1. Marketing Strategy
      • 22.2.10.6.2. Service Strategy
      • 22.2.10.6.3. Channel Strategy
  • 22.2.11. Fujifilm Diosynth Biotechnologies
    • 22.2.11.1. Overview
    • 22.2.11.2. Service/Product Portfolio
    • 22.2.11.3. Sales Footprint
    • 22.2.11.4. Key Financials
    • 22.2.11.5. SWOT Analysis
    • 22.2.11.6. Strategy Overview
      • 22.2.11.6.1. Marketing Strategy
      • 22.2.11.6.2. Service Strategy
      • 22.2.11.6.3. Channel Strategy
  • 22.2.12. Xpress Biologic
    • 22.2.12.1. Overview
    • 22.2.12.2. Service/Product Portfolio
    • 22.2.12.3. Sales Footprint
    • 22.2.12.4. Key Financials
    • 22.2.12.5. SWOT Analysis
    • 22.2.12.6. Strategy Overview
      • 22.2.12.6.1. Marketing Strategy
      • 22.2.12.6.2. Service Strategy
      • 22.2.12.6.3. Channel Strategy
  • 22.2.13. Rentschler Biopharma SE
    • 22.2.13.1. Overview
    • 22.2.13.2. Service/Product Portfolio
    • 22.2.13.3. Sales Footprint
    • 22.2.13.4. Key Financials
    • 22.2.13.5. SWOT Analysis
    • 22.2.13.6. Strategy Overview
      • 22.2.13.6.1. Marketing Strategy
      • 22.2.13.6.2. Service Strategy
      • 22.2.13.6.3. Channel Strategy
  • 22.2.14. KBI Biopharma (JSR Corporation)
    • 22.2.14.1. Overview
    • 22.2.14.2. Service/Product Portfolio
    • 22.2.14.3. Sales Footprint
    • 22.2.14.4. Key Financials
    • 22.2.14.5. SWOT Analysis
    • 22.2.14.6. Strategy Overview
      • 22.2.14.6.1. Marketing Strategy
      • 22.2.14.6.2. Service Strategy
      • 22.2.14.6.3. Channel Strategy
  • 22.2.15. Cytovance Biologics
    • 22.2.15.1. Overview
    • 22.2.15.2. Service/Product Portfolio
    • 22.2.15.3. Sales Footprint
    • 22.2.15.4. Key Financials
    • 22.2.15.5. SWOT Analysis
    • 22.2.15.6. Strategy Overview
      • 22.2.15.6.1. Marketing Strategy
      • 22.2.15.6.2. Service Strategy
      • 22.2.15.6.3. Channel Strategy

23. Assumptions and Acronyms Used

24. Research Methodology

관련자료